Succesful feasibility study for the development of topical medical cannabis products

Cannassure Therapeutics Ltd (TASE: CSURE) (“Cannassure”), an Israel based developer and producer of innovative medical cannabis products, announces today the successful completion of a feasibility study for the development of IP protected, homogeneous, topical medical Cannabis products for the treatment of skin inflammation, including psoriatic lesions. (PRESS RELEASE) Product development of such topical medical ... Read More

Lipidor announces positive outcome of feasibility study for development of topical medical cannabis products based on the company's AKVANO technology

STOCKHOLM, Sept. 30, 2020 /PRNewswire/ — Lipidor AB (Nasdaq First North:LIPI) today announces a positive outcome of the feasibility study into the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The study was conducted in collaboration with Cannassure Therapeutics Ltd. , an Israeli ... Read More